Evidence map›Paper›PMID 26675585›Full record

ArticleBBA clinical2015

Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients.

George Boon-Bee Goh, Mangesh R Pagadala, Jaividhya Dasarathy, Aynur Unalp-Arida, Ruth Sargent, Carol Hawkins, Achuthan Sourianarayanane, Amer Khiyami, Lisa Yerian, Rish K Pai and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BBA clinical, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. PMEnvironmental research · 2022
    Article
  16. Article
  17. Article
  18. Evaluation of the Impact of Metabolic Syndrome on Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2021
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

George Boon-Bee GohDepartment of Gastroenterology at Cleveland Clinic, USA.
Mangesh R PagadalaDepartment of Gastroenterology at Cleveland Clinic, USA.
Jaividhya DasarathyDepartment of Family Medicine at MetroHealth Medical Center, USA.
Aynur Unalp-AridaDepartment of Public Health at Johns Hopkins University, USA.
Ruth SargentDepartment of Gastroenterology at Cleveland Clinic, USA.
Carol HawkinsDepartment of MetroHealth Medical Center, USA.
Achuthan SourianarayananeDepartment of Gastroenterology at Cleveland Clinic, USA.
Amer KhiyamiDepartment of MetroHealth Medical Center, USA.
Lisa YerianDepartment of Pathology at Cleveland Clinic, USA.
Rish K PaiDepartment of Pathology at Cleveland Clinic, USA.
Srinivasan DasarathyDepartment of Gastroenterology at Cleveland Clinic, USA ; Department of Pathobiology at Cleveland Clinic, USA.
Arthur J McCulloughDepartment of Gastroenterology at Cleveland Clinic, USA ; Department of Pathobiology at Cleveland Clinic, USA.
Cleveland Clinic · USMetroHealth Medical Center · USJohns Hopkins University · USMetroHealth · US

Funding

Training Program in Academic GastroenterologyT32DK061917 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI COOPER, GREGORY S. · 2002 to 2006
$795k
NIDDK NIH HHS T32 DK061917
6 · The paper itself

Abstract

backgroundWhile non-alcoholic fatty liver disease (NAFLD) has been well characterised in patients with diabetes mellitus (DM), less is known about NAFLD in non-DM patients. We investigated the clinical characteristics of NAFLD patients with and without DM and accuracy of the NAFLD fibrosis score (NFS) in these two NAFLD groups.

methodsClinical, biochemical and histological variables were evaluated in this prospective cross-sectional study of 503 patients with biopsy proven NAFLD. Comparisons between patients with and without DM were analysed. NFS was correlated with liver histology to assess its robustness in patients with and without DM.

resultsThere were 503 biopsy proven NAFLD patients with 48% of the cohort being diabetic. Relative to patients without DM, patients with DM were older (52 vs. 46 years, p < 0.001), with higher proportion of females (70% vs. 54%, p < 0.001), higher BMI (37 vs. 35, p = 0.009), higher prevalence of hypertension (73% vs. 44%, p < 0.001), higher prevalence of NASH (80.2% vs. 64.4%; p < 0.001) and advanced fibrosis (40.3% vs. 17.0%; p < 0.001). A considerable amount of patients without DM still had NASH (64%) and advanced fibrosis (17%). The clinical utility of the NFS differed between NAFLD patients with and without DM, with sensitivity to exclude advanced fibrosis being 90% of NAFLD patients with DM but only 58% of patients without DM.

conclusionPatients with DM have more severe NAFLD based on histology. However, NASH and advanced fibrosis also occur in a considerable proportion of NAFLD patients without DM. The lower utility of the NFS in NAFLD patients without DM emphasises the heterogeneous nature of the NAFLD phenotype.

Indexed as

ACE-I, angiotensin-converting enzyme-inhibitorALP, alkaline phosphataseALT, alanine aminotransferaseapoB-100, apolipoprotein B-100ARB, angiotensin receptor blockerAST, aspartate aminotransferaseBMI, body mass indexChol, total cholesterolCIs, confidence intervalsDiabeticDM, type 2 diabetes mellitusER, endoplasmic reticulumFFAs, free-fatty acidsHDL, high density lipoprotein cholesterolHOMA-IR, Homeostatic model assessment—insulin resistanceINR, international normalised ratioLDL, low density lipoprotein cholesterolNAFLDNAFLD fibrosis scoreNAFLD, non-alcoholic fatty liver diseaseNASH CRN, Non-alcoholic Steatohepatitis Clinical Research NetworkNASH, non-alcoholic steatohepatitisNAS, NAFLD activity scoreNFS, NAFLD fibrosis scoreNon-diabeticORs, odd ratiosSDs, standard deviationsTGs, triglyceridesVLDL, very-low-density lipoproteins

Identifiers

PMID26675585
PMCPMC4661498
OpenAlexW2088076828

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.